RevvityBSP:R1VT34 +5.03%17 Net Margin % is 5.73% as of Mar. 2026, which is 52% below its 10-year median of 12.03. GuruFocus rates BSP:R1VT34 with a GF Score™ of 17/100 and a GF Value™ of R$22.14 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Revvity ranks better than 71.08% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Revvity's Net Income for the
three
months ended in Mar. 2026 was R$213 Mil. Revvity's Revenue for the
three
months ended in Mar. 2026 was R$3,719 Mil. Therefore, Revvity's net margin for the quarter that ended in Mar. 2026 was 5.73%.
The historical rank and industry rank for Revvity's Net Margin % or its related term are showing as below:
BSP:R1VT34'
s Net Margin % Range Over the Past 10 Years
Min: 7.89 Med: 12.03 Max: 27.33
Current: 8.26
BSP:R1VT34's Net Margin % is ranked better than 71.08% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs BSP:R1VT34: 8.26
Revvity (BSP:R1VT34) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Revvity Net Margin % Related Terms
Revvity Net Margin % Historical Data
* Premium members only.
The historical data trend for Revvity's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:R1VT34 vs MEDP, ICLR, CRL: Net Margin % Comparison
For the Diagnostics & Research subindustry, Revvity's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Net Margin % distribution charts can be found below:
* The bar in red indicates where Revvity's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (BSP:R1VT34) has a Net Margin % of 5.73% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Revvity and its competitors. This is 52% below median its historical median of 12.03. Over the past decade, Revvity's Net Margin % has ranged from 7.89 to 27.33. According to the industry distribution chart, Revvity ranks #59 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 28.9%.
Is Revvity's Net Margin % too high?
Revvity's current Net Margin % of 5.73% is 52% below median its 10-year median of 12.03. Over the past 10 years, this metric has ranged from a low of 7.89 to a high of 27.33. Based on the distribution chart, Revvity ranks #59 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Revvity has a GF Score™ of 17/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Revvity's Net Margin % compare to MEDP and ICLR?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #59 out of 204 companies for Net Margin %. This puts Revvity in the upper half of its industry. Historically, Revvity's own Net Margin % has ranged from 7.89 to 27.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Revvity and its competitors. Revvity's current Net Margin % is 5.73%, which is 52% below median its own 10-year median of 12.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (BSP:R1VT34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$22.14, compared to a current price of R$19.41 — trading 12.3% below its estimated fair value. The current Net Margin % is 5.73%, which is 52% below median its 10-year median of 12.03. Revvity's overall GF Score™ is 17/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Revvity (BSP:R1VT34), the current Net Margin % is 5.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (BSP:R1VT34) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of R$19.41 is trading 12.3% below its estimated GF Value™ of R$22.14.
GuruFocus considers Revvity to be Modestly Undervalued.
Key valuation signals for BSP:R1VT34:
Net Margin %: 5.73% (52% below median its 10-year median of 12.03)
GF Value™: R$22.14 vs. price of R$19.41 (12.3% below fair value)
No single metric tells the full story. See the BSP:R1VT34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
17GF Score
Get the complete analysis for BSP:R1VT34
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:R1VT34 has been successfully added to your 
